Document:

<PAGE>
                                                                   EXHIBIT 10.16

                          EXCLUSIVE LICENSE AGREEMENT

                                    between

                  THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

                                      and

                                  NANOSYS INC.

                                      for

                                 [*** Redacted]

                              UC Case No. [*** Redacted]

                                                       U.C. AGREEMENT
                                                       CONTROL NUMBER
                                                       [*** Redacted]

*** Confidential treatment requested pursuant to a request for confidential
treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission.
<PAGE>
                               TABLE OF CONTENTS

Article No.     Title                                                       Page

BACKGROUND...................................................................  2

1.  DEFINITIONS..............................................................  3

2.  LIFE OF PATENT EXCLUSIVE GRANT...........................................  5

3.  SUBLICENSES..............................................................  5

4.  PAYMENT TERMS............................................................  8

5.  LICENSE ISSUE FEE......................................................... 9

6.  EARNED ROYALTIES AND MINIMUM ANNUAL ROYALTIES............................  9

7.  DUE DILIGENCE............................................................ 11

8.  PROGRESS AND ROYALTY REPORTS............................................. 12

9.  BOOKS AND RECORDS........................................................ 14

10. LIFE OF THE AGREEMENT.................................................... 14

11. TERMINATION BY THE REGENTS............................................... 15

12. TERMINATION BY LICENSEE.................................................. 15

13. DISPOSITION OF LICENSED PRODUCT ON HAND UPON TERMINATION................. 15

14. USE OF NAMES AND TRADEMARKS.............................................. 16

15. LIMITED WARRANTY......................................................... 16

16. PATENT PROSECUTION AND MAINTENANCE....................................... 17

17. PATENT MARKING........................................................... 19

18. PATENT INFRINGEMENT...................................................... 19

19. INDEMNIFICATION.......................................................... 20

20. NOTICES.................................................................. 21

21. ASSIGNABILITY............................................................ 22

22. NO WAIVER................................................................ 23

23. FAILURE TO PERFORM....................................................... 23

24. GOVERNING LAWS........................................................... 23

25. PREFERENCE FOR U.S. INDUSTRY............................................. 23

26. GOVERNMENT APPROVAL OR REGISTRATION...................................... 23

27. EXPORT CONTROL LAWS...................................................... 23

28. SECRECY.................................................................. 24

29. MISCELLANEOUS............................................................ 25

                                       1

<PAGE>
                          EXCLUSIVE LICENSE AGREEMENT

                                      for

                                 [*** Redacted]

     This exclusive license agreement ("Agreement") is made effective May 31,
2002 ("Effective Date"), between The Regents of the University of California, a
California corporation, having its statewide administrative offices at 1111
Franklin Street, 12th Floor, Oakland, California 94607-5200 ("The Regents"),
and Nanosys, Inc, a Delaware corporation, having a principal place of business
at 200 Boston Avenue, Suite 4700, Medford, MA 02155 ("Licensee").

                                   BACKGROUND

     A. Certain inventions, generally characterized as [*** Redacted]
(collectively "Invention"), were made in the course of research at the
University of California, Berkeley, the University of California, Santa Cruz,
and the Lawrence Berkeley National Laboratory and are covered by Regents' Patent
Rights as defined below.

     B. The development of the Invention was sponsored in part by the National
Science Foundation and the Department of Energy and, as a consequence, this
license is subject to overriding obligations to the United States ("U.S.")
Federal Government under 35 U.S.C. Sections 200-212 and applicable regulations
including a non-exclusive paid up license for or on behalf of the United States
throughout the world.

     C. Licensee and The Regents have executed a Letter of Intent (UC Control
No. [*** Redacted]) dated September 13, 2001.

     D. Licensee and The Regents have executed a Secrecy Agreement (UC Control
No. [*** Redacted]) effective February 8, 2002.

     E. Licensee wishes to obtain rights from the Regents for the exclusive
commercial development, use and sale of products from the Invention, and the
Regents is willing to grant those

                                                       U.C. AGREEMENT
                                                       CONTROL NUMBER
                                                       [*** Redacted]

*** Confidential treatment requested pursuant to a request for confidential
treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission.

                                       2
<PAGE>
rights so that the Invention may be developed to its fullest and the benefits
enjoyed by the general public.

     F. Licensee is a "small business firm" as defined in 15 U.S.C. Section 632.

     G. Both parties recognize and agree that royalties due under this
Agreement on products and methods will be paid by Licensee on both pending
patent applications and issued patents.

                                 -- oo 0 oo --

     In view of the foregoing, the parties agree:

1.   DEFINITIONS

     1.1 "Affiliate" means any corporation or other business entity in which
Licensee owns or controls, directly or indirectly, at least fifty percent (50%)
of the outstanding stock or other voting rights entitled to elect directors or
in which Licensee is owned or controlled directly or indirectly by at least
fifty percent (50%) of the outstanding stock or other voting rights entitled to
elect directors; but in any country where the local law does not permit foreign
equity participation of at least fifty percent (50%), then an "Affiliate"
includes any company in which Licensee owns or controls, or is owned or
controlled by, directly or indirectly, the maximum percentage of outstanding
stock or voting rights permitted by local law.

     1.2 "Licensed Method" means any method, the use of which would constitute,
but for the license granted to Licensee under this Agreement, an infringement
of any Valid Claim within Regents' Patent Rights.

     1.3 "Licensed Product" means any material that is produced by the Licensed
Method or that the sale of which would constitute, but for the license granted
to Licensee under this Agreement, an infringement of any Valid Claim within
Regents' Patent Rights.

     1.4 "Net Sales" means the [*** Redacted] received by Licensee or its
Affiliates from the [*** Redacted]

*** Confidential treatment requested pursuant to a request for confidential
treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission.

                                       3
<PAGE>
[*** Redacted]. For purposes of calculating Net Sales, any distribution or
transfer between Licensee (or an Affiliate) and a sublicensee for end use by the
recipient (which event is the last act of infringement of Regents' Patent
Rights) will be considered a Final Sale at the price normally charged to
independent, unaffiliated third parties.

     [*** Redacted]

     If the Licensed Product is a part or an optional component of a system,
Licensee agrees that any discounting of price will be done uniformly and equally
across the system so that the Licensed Product is not discounted any more than
the system as a whole.

     1.5 "Regents' Patent Rights" means The Regents' interest in the following
subject matter:

<Table>
<Caption>
UC Case Number                U.S. Application Number            Filing Date
--------------                -----------------------            -----------
<S>                                <C>                         <C>
[*** Redacted]                      [*** Redacted]              [*** Redacted]
[*** Redacted]                      [*** Redacted]              [*** Redacted]
[*** Redacted]                      [*** Redacted]              [*** Redacted]
[*** Redacted]                      [*** Redacted]              [*** Redacted]
</Table>

     and continuing applications thereof including divisions, continuations,
continued prosecution applications, or substitutions, and continuation-in-part
applications or patents of additions (to the extent claims of such
continuations-in-part or patents of additions are supported by the parent
application); any patents on said applications including reissues,
reexaminations, registrations, renewals and extensions; any corresponding
foreign applications or patents; and any other patents

*** Confidential treatment requested pursuant to a request for confidential
treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission.

                                       4
<PAGE>
and patent applications worldwide based upon and claiming any inventions
described in the above patents and patent applications.

     1.6  "Valid Claim" shall mean either (i) a claim of an issued patent that
has not expired or been held unenforceable or invalid by a final judgment or
decision of a court or other government agency of competent jurisdiction from
which no appeal has or can be taken, and which has not been admitted to be
invalid or unenforceable through reissue, disclaimer or otherwise, or (ii) a
claim of a pending patent application that is being prosecuted in good faith
consistent with customary patent practice, which has not been abandoned or
finally rejected without the possibility of appeal or refiling and has been
pending for less than [*** Redacted] ([*** Redacted]) [*** Redacted] in the
United States or [*** Redacted] ([*** Redacted]) [*** Redacted] in foreign
countries after its earliest priority date.

2.   LIFE OF PATENT EXCLUSIVE GRANT

     2.1  Subject to the limitations set forth in this Agreement, The Regents
grants to Licensee a world-wide license under Regents' Patent Rights to make,
have made, use, sell, offer to sell and import Licensed Products and to
practice Licensed Methods to the extent permitted by law, in each case for any
and all fields of use.

     2.2  Except as otherwise provided in this Agreement, the license granted
in Paragraph 2.1 is exclusive for the life of the Agreement.

     2.3  The license granted in Paragraphs 2.1 and 2.2 is subject to all the
applicable provisions of any license to the U.S. Government executed by The
Regents prior to the Effective Date and is subject to the overriding obligations
to the U.S. Government under 35 U.S.C. Sections 200-212 and applicable
governmental implementing regulations.

     2.4  The Regents reserves the right to use the Invention and technology of
the Patent Rights for educational and non-commercial research purposes
including publication of research results and sharing such research results,
such Invention and technology with other educational and non-profit
institutions for their use of similar scope.

3.   SUBLICENSES

     3.1  The Regents also grants to Licensee the right to issue sublicenses to
third parties to make, have made, use, sell, offer to sell and import Licensed
Product and to practice Licensed Method, and other sublicenses of or within the
scope of the license granted under Article 2, as long as Licensee has current
exclusive rights thereto under this Agreement. To the extent applicable,

*** Confidential treatment requested pursuant to a request for confidential
treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission.

                                       5
<PAGE>
sublicenses must include all of the rights of and obligations due to The
Regents and, if applicable, the U.S. Government contained in this Agreement.

     3.2  Licensee shall promptly provide The Regents with a copy of the
relevant portion of each sublicense issued (which shall include but not be
limited to information with an impact on financial terms or other requirements
of this Agreement), collect and guarantee payment of all payments due The
Regents from sublicensees and summarize and deliver all reports due The Regents
from sublicensees. All such information shall be deemed the Confidential
Information of Licensee pursuant to the terms of Article 28 (Secrecy).

     3.3  (a) If after [*** Redacted] ([*** Redacted]) [*** Redacted] from the
Effective Date, The Regents becomes aware of any field of use that Licensee is
not pursuing with respect to the Regents' Patent Rights, and a third party has
an interest and a detailed plan for pursuing such field of use (which is not
overlapping or competitive with any field pursued by Licensee for Regent's
Patent Rights), The Regents may notify Licensee of such third party's interest
(such third party, the "Potential Sublicensee", and such field, the "New
Field").

     (b) In the event of a notice under Section 3.3(a), Licensee shall have a
period of [*** Redacted] ([*** Redacted]) [*** Redacted] thereafter to notify
The Regents (such notice, its "New Field Plans") if: (i) it or its sublicensees
are then currently pursuing the New Field (or an overlapping or competitive
field of use for Regent's Patent Rights); or (ii) it or its sublicensees are
planning to pursue the New Field (or an overlapping or competitive field of use
for Regent's Patent Rights) in the future; or (iii) it desires to directly
sublicense such Potential Sublicensee. If Licensee notifies The Regents of case
(i) or (ii) above, Licensee or its sublicensee shall provide The Regents with
its development plan therefor within [*** Redacted] ([*** Redacted]) [***
Redacted] thereafter. If Licensee notifies The Regents of case (iii) above, The
Regents shall direct the Potential Sublicensee to negotiate in good faith with
Licensee for a sublicense.

     (c) If (i) Licensee has not notified The Regents of its New Field Plans
within the above [*** Redacted] ([*** Redacted]) [*** Redacted] period or
Licensee has not provided The Regents with a development plan therefor within
the above [*** Redacted] ([*** Redacted]) [*** Redacted] period, as required in
Section 3.3(b), or (ii) Licensee and the Potential Sublicensee are unable to
reach a sublicense agreement, and the Potential Sublicensee has negotiated in
good faith with Licensee, or (iii) Licensee fails to diligently proceed in good
faith with the development, manufacture, and sale of Licensed Product in New
Field according to the development plan of 3.3(b), as updated from time to time
with the approval of The Regents, then The Regents may issue a non-exclusive
sublicense to the Potential Sublicensee, limited to the New

*** Confidential treatment requested pursuant to a request for confidential
treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission.

                                       6
<PAGE>
Field; provided that Licensee does not notify The Regents that it owns or
controls issued patent claims, which patent claims are valid and would dominate
use of the Regents' Patent Rights in the New Field. Such sublicense to the
Potential Sublicensee shall have royalty rate(s) (including with respect to
sublicensing revenue) which are no more favorable than those set forth herein.

     3.4  Upon termination of this Agreement for any reason, all sublicenses of
The Regents' Patent Rights not then currently in material breach, will be
assigned to The Regents, at the request of the sublicensee; provided that the
duties of The Regents under the assigned sublicenses will not be greater than
the duties of The Regents under this Agreement, and the rights of The Regents
under the assigned sublicenses will not be less than the rights of The Regents
under this Agreement.

     3.5  Payment to The Regents for sublicenses of Regent's Patent Rights
issued by Licensee to non-Affiliate third parties shall include payment of [***
Redacted]% of all fees, royalties and other revenues obtained by the Licensee
from such sublicense, but excluding (a) income received by Licensee as payment
or reimbursement for research, development or costs incurred by or for Licensee
associated with materials, equipment or clinical testing or patent expenses (as
reasonably allocated, and according to fair market value if readily available);
(b) amounts received for securities (equity or debt), or services, products,
equipment (as reasonably allocated, and according to fair market value if
readily available); (c) amounts in consideration for licenses or other rights
under intellectual property other than Regents' Patent Rights, as reasonably
allocated; (d) amounts in consideration for the sale of all or substantially all
of the business or assets of Licensee, whether by merger, acquisition of stock
or assets or otherwise; and (e) any governmental charges, including withholding
or other taxes (but not income taxes), paid or payable by Licensee on amounts
received in consideration for a sublicense under Regents' Patent Rights. In the
event that such payment to Licensee for issuance of a sublicense includes a
non-cash component, including but not limited to equipment and cross-licenses,
the Regents shall be paid [*** Redacted]% of the value of the non-cash component
(excluding deductions (a) to (e) above). Upon request, Licensee shall provide
the Regents with its calculation of the above amounts, along with supporting
documentary evidence.

     3.6  Implicit in the [*** Redacted]% figure of Paragraph 3.5 above is the
assumption that Licensee will add significant value to Regents' Patent Rights
through its own development efforts. In the event that Licensee issues a
sublicense that does not include a contribution of Licensee's development or
Licensee has not added significant value, payment to The Regents for that
sublicense shall be [*** Redacted]% rather than [*** Redacted]%. Without
limiting the generality of such language, Licensee shall be deemed to have

*** Confidential treatment requested pursuant to a request for confidential
treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission.

                                       7
<PAGE>
contributed development or added significant value if Licensee sublicenses other
patent rights or provides other substantive intellectual property or technology
(e.g. manufacturing know-how, prototypes, breadboards, components or tools) in
connection with sublicensing the Regents' Patent Rights, or Licensee has spent
at least [*** Redacted] dollars ($[*** Redacted]) developing Licensed Products
or Licensed Methods (within the meaning stated in Section 7.3), which
development efforts are in or applicable to the field of use being sublicensed.

4.   PAYMENT TERMS

     4.1  Paragraphs 1.2, 1.3 and 1.5 define Licensed Method, Licensed Product
and Regents' Patent Rights, so that royalties are payable on products and
methods covered by Valid Claims of both pending patent applications and issued
patents. Royalties will accrue in each country for the duration of Regents'
Patent Rights in that country and are payable to The Regents in the next
royalty report after payment for the Licensed Product is received by Licensee
or Affiliate.

     4.2  Licensee shall pay to The Regents earned royalties quarterly on or
before [*** Redacted] of each calendar year. Each payment will be for earned
royalties accrued within Licensee's most recently completed [*** Redacted].

     4.3  All monies due The Regents are payable in U.S. dollars. Licensee is
responsible for all bank transfer charges. When Licensed Product is sold for
monies other than U.S. dollars, Licensee shall first determine the earned
royalty in the currency of the country in which Licensed Product was sold and
then convert the amount into equivalent U.S. funds, using the exchange rate
quoted in The Wall Street Journal on the last business day of the reporting
period.

     4.4  Royalties earned on sales occurring in any country outside the U.S.
may not be reduced by any taxes, fees or other charges imposed by the
government of such country on the payment of royalty income. Notwithstanding
the foregoing, all payments made by Licensee in fulfillment of The Regents' tax
liability in any particular country will be credited against earned royalties
or fees due The Regents for that country.

     4.5  If at any time legal restrictions prevent the prompt remittance of
royalties by Licensee from any country where a Licensed Product is sold, then
Licensee shall convert the amount owed to The Regents into U.S. funds and shall
pay The Regents directly from its U.S. source of funds for as long as the legal
restrictions apply.

     4.6  If any patent or patent claim within Regents' Patent Rights is held
invalid in a final decision by a court of competent jurisdiction and last
resort and from which no appeal has or can be

*** Confidential treatment requested pursuant to a request for confidential
treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission.

                                       8
<PAGE>
taken, then all obligation to pay royalties based on that patent or claim or
any claim patentably indistinct therefrom will cease as of the date of final
decision. Licensee will not, however, be relieved from paying any royalties
that accrued before the final decision or that are based on another patent or
claim not involved in the final decision.

     4.7  No royalties may be collected or paid on Licensed Product sold to the
account of the U.S. Government, or any agency thereof, as provided for in the
license to the Government.

     4.8  In the event payments, rebillings or fees are not received by The
Regents when due, Licensee shall pay to The Regents interest charges at a rate
of [*** Redacted] percent ([*** Redacted]%) per annum. Interest is calculated
from the date payment was due until actually received by The Regents.

5.  LICENSE ISSUE FEE

          Licensee shall pay to The Regents a license issue fee of [***
Redacted] ([*** Redacted]) within thirty (30) days after the Effective Date.
Licensee shall, as a one-time payment, pay The Regents an additional [***
Redacted] ([*** Redacted]) within [*** Redacted]. These fees are non-refundable,
non-cancelable and are not an advance against royalties.

6.  EARNED ROYALTIES AND MINIMUM ANNUAL ROYALTIES

     6.1  Licensee shall also pay to The Regents an earned royalty of [***
Redacted] percent ([*** Redacted]%) of the Net Sales of Licensed Product or
Licensed Method.

     6.2  In the event that Licensee must pay additional royalties on the sale
of a Licensed Product or Licensed Method to one or more independent,
unaffiliated third parties (who have patent rights that are required to make or
sell the Licensed Product or Licensed Method), and the sum of royalties to be
paid by Licensee (prior to any reductions) to all such third parties (such
royalty for each individual third party, a "Third Party Royalty" and the sum,
the "Total Royalties") would exceed [*** Redacted] percent ([*** Redacted]%),
then The Regents will agree to reduce the royalties due on that Licensed Product
or Licensed Method by multiplying with the ratio [*** Redacted], where X is the
percentage value of the Total Royalties; provided that each such third party
also agrees to a reduction of its royalty rate to an amount equal to or less
than Y, where Y is equal to the corresponding Third Party Royalty multiplied
with the ratio [*** Redacted]. If any such third party does not reduce its
royalty rate to at least Y, then The Regents shall reduce its royalty rate by a
percentage equal to the minimum reduction

*** Confidential treatment requested pursuant to a request for confidential
treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission.

                                       9
<PAGE>
(percentage wise) agreed to by such third parties. However, in no case shall
royalties due The Regents according to Paragraph 6.1 be reduced to less than
[*** Redacted] percent ([*** Redacted]%).

     For example: If Licensee licenses intellectual property rights from two
other entities E1 and E2 for use in Licensed Products, at the respective royalty
rates of [*** Redacted]% and [*** Redacted]%, the total royalties before a
proportionate reduction is equal to [*** Redacted]. The Regents will then agree
to reduce its royalty rate at a ratio of [*** Redacted], i.e. to [***
Redacted]%, if the other licensing entities E1 and E2 agree to reduce their
royalty rate to [*** Redacted]% or below.

<Table>
<Caption>
Licensing entity       Initial royalty rate      ratio      Reduced royalty rate
<S>                    <C>                   <C>            <C>
The Regents            [*** Redacted]%       [*** Redacted] [*** Redacted]%

E1                     [*** Redacted]%       [*** Redacted] [*** Redacted]%

E2                     [*** Redacted]%       [*** Redacted] [*** Redacted]%

Total:                 [*** Redacted]%       [*** Redacted] [*** Redacted]%
</Table>

     6.3  To implement a reduction in royalties due under Paragraph 6.2,
Licensee will provide written evidence of license agreements with third parties
that include the third parties' agreement to a reduction in royalties due to
them sufficient under Paragraph 6.2. Licensee shall provide written evidence of
payments made to such third parties under such license agreements.

     6.4  Licensee shall pay to The Regents a minimum annual royalty as follows:

     -    [*** Redacted] dollars ([*** Redacted]) in [*** Redacted];

     -    [*** Redacted] dollars ([*** Redacted]) in [*** Redacted];

     -    [*** Redacted] dollars ([*** Redacted]) in [*** Redacted];

     -    [*** Redacted] dollars ([*** Redacted]) in [*** Redacted];

     -    [*** Redacted] dollars ([*** Redacted]) in [*** Redacted];

     -    [*** Redacted] dollars ([*** Redacted]) in [*** Redacted];

     -    and beginning in [*** Redacted] and for the remaining life of Regents'
Patent Rights, Licensee shall pay to The Regents a minimum annual royalty of
[*** Redacted] dollars ([*** Redacted]).

     The minimum annual royalty will be paid to The Regents by [*** Redacted] of
each year and will be credited against the earned royalty due for the calendar
year in which the minimum payment was made.

*** Confidential treatment requested pursuant to a request for confidential
treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission.

                                       10
<PAGE>
     6.5  In no event shall more than one royalty be payable hereunder with
respect to any particular Licensed Product unit or practice of Licensed Method.
No royalty shall be payable under this Agreement with respect to sales of
Licensed Products among Licensee, its Affiliates or sublicensees for resale;
nor shall a royalty be payable hereunder with respect to the practice of
Licensed Methods or the sale or provision of Licensed Products as samples, for
research and development efforts by or for Licensee, or transactions that are
not a full commercial sale (i.e. for transactions that are at fully burdened
cost or for which there is no profit).

     6.6  The amounts payable under this Agreement are based on the parties'
understanding that The Regents owns or controls sufficient right, title and
interest in each of the patent rights listed in the table of Section 1.5 to
grant Licensee an exclusive license thereunder apart from the license to the
government hereunder. In the event The Regents breaches this Section 6.6 (i.e.
it does not have such ownership or control), then the parties shall negotiate
in good faith to appropriately reduce the amounts payable under this Agreement,
in addition to any other remedies which may be available.

7.   DUE DILIGENCE

     7.1  Licensee, upon execution of this Agreement, shall diligently proceed
with the development, manufacture and sale of Licensed Product and shall
earnestly and diligently endeavor to market the same within a reasonable time
after execution of this Agreement and in quantities sufficient to meet market
demands, each to the extent commercially sound and technically viable.

     7.2  Licensee shall endeavor to obtain all necessary governmental
approvals for the manufacture, use and sale of Licensed Product.

     7.3  Licensee shall:

          7.3.1  Employ [*** Redacted] ([*** Redacted]) [*** Redacted] (or the
                 equivalent if employees' time is devoted to multiple projects)
                 to work solely on Invention by [*** Redacted];

          7.3.2  Employ [*** Redacted] ([*** Redacted]) [*** Redacted] (or the
                 equivalent if employees' time is devoted to multiple projects)
                 to work solely on Invention by [*** Redacted];

          7.3.3  use commercially reasonable efforts to achieve a first
                 commercial sale of a Licensed Product or Licensed Method by
                 [*** Redacted];

          7.3.4  reasonably fill the market demand for Licensee's Licensed
                 Products following commencement of marketing and at any time
                 during the exclusive period of this Agreement, to the extent
                 commercially sound and technically viable;

*** Confidential treatment requested pursuant to a request for confidential
treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission.

                                       11
<PAGE>
          7.3.5  spend at least [*** Redacted] dollars ($[*** Redacted]) on
                 development of Licensed Product or Licensed Method by December
                 31, 2003;

          7.3.6  spend at least [*** Redacted] dollars ($[*** Redacted])
                 annually on development of Licensed Product or Licensed Method
                 starting in 2004, until the first commercial sale of a Licensed
                 Product or Licensed Method.

     It is understood that "working solely on" the Invention and "developing"
Licensed Products or Licensed Methods shall include working on, developing or
acquiring technology reasonably necessary for the commercial and/or technical
viability of the Regent's Patent Rights or any Licensed Product or Licensed
Method (e.g. interface, electronic packaging, device integration, materials
and/or fabrication technologies).

     7.4  If Licensee is unable to perform Sections 7.1, 7.2 or 7.3, then The
Regents has the right to reduce Licensee's exclusive license to a nonexclusive
license (in the event Licensee is unable to perform Sections 7.3.1, 7.3.2,
7.3.5, 7.3.6, The Regents may, at its option, terminate the license under
Section 11 or render the license non-exclusive) upon written notice; provided in
each case, that The Regents' has notified Licensee of its breach of such
Sections, and has negotiated in good faith with Licensee with respect to a
mutually acceptable plan to remedy such breach, and Licensee then fails to
perform such mutually acceptable plan. If the parties cannot reach agreement on
a mutually acceptable plan, the mutually acceptable plan shall be for Licensee
to thereafter: (a) continue to be subject to all of its diligence requirements,
and (b) spend an extra [*** Redacted] percent ([*** Redacted]%) of the amounts
it is obligated to spend over the same period under Sections 7.3.5 and 7.3.6.
Licensee's compliance with the mutually acceptable plan shall be subject, as a
minimum, to Regents' verification [*** Redacted] ([*** Redacted]) [*** Redacted]
thereafter of Licensee's progress. This right, if exercised by The Regents,
supersedes the rights granted in Article 2 (Life of Patent Exclusive Grant).

8.   PROGRESS AND ROYALTY REPORTS

     8.1  Beginning September 30, 2003, and semi-annually thereafter, Licensee
shall submit to The Regents a written progress report covering Licensee's (and
any Affiliate's or sublicensee's) activities related to the development and
testing of Licensed Products and the obtaining of the governmental approvals
necessary for marketing. Progress reports are required until the first
commercial sale of a Licensed Product occurs in the U.S. and shall be again
required if commercial sales of all Licensed Products are suspended or
discontinued. All reports under this Article 7 shall be deemed the Confidential
Information of Licensee pursuant to the terms of Article 28 (Secrecy).

*** Confidential treatment requested pursuant to a request for confidential
treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission.

                                       12
<PAGE>
     8.2  Progress reports submitted under Paragraph 8.1 shall include, but are
not limited to, the following topics:

          8.2.1  a statement specifically addressing each diligence requirement
                 of Article 7 (DUE DILIGENCE),

          8.2.2  summary of work completed,

          8.2.3  key scientific discoveries;

          8.2.4  summary of work in progress,

          8.2.5  current schedule of anticipated events or milestones,

          8.2.6  market plans for introduction of Licensed Product, and

          8.2.7  a summary of resources (dollar value) spent in the reporting
                 period.

     8.3  Licensee has a continuing responsibility to keep The Regents informed
of the large or small business entity status (as defined by the U.S. Patent and
Trademark Office) of itself and its sublicensees and Affiliates.

     8.4  Licensee shall report to The Regents in its immediately subsequent
progress and royalty report the date of first commercial sale of a Licensed
Product in each country.

     8.5    After the first commercial sale of a Licensed Product anywhere in
the world, Licensee shall make quarterly royalty reports to The Regents on or
before each February 28 (for the quarter ending December 31) May 31 (for the
quarter ending March 31), August 31 (for the quarter ending June 30) and
November 30 (for the quarter ending September 30) of each year. Each royalty
report will cover Licensee's most recently completed calendar quarter and will
show:

     8.5.1  the gross sales and Net Sales of Licensed Product sold during the
most recently completed calendar quarter;

     8.5.2  the number of each type of Licensed Product sold;

     8.5.3  the royalties, in U.S. dollars, payable with respect to sales of
Licensed Product;

     8.5.4  the method used to calculate the royalty;

     8.5.5  the exchange rates used;

     8.5.6  a justification in writing for the values of A and B along with the
method of their calculation if combination products are sold and Licensee wishes
to apply the [*** Redacted] as discussed in Paragraph 1.4 "Net Sales"; and

     8.5.7  written evidence of license agreements with third parties that
include the third parties' agreement to a proportional reduction in royalties
due, evidence of payments made to such third

*** Confidential treatment requested pursuant to a request for confidential
treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission.

                                       13
<PAGE>
parties under such license agreements, and the method of calculation of the
reduced royalty rate if Licensee wishes to implement a reduction in royalties
due under Paragraph 6.2.

     8.6  If no sales of Licensed Product have been made during any reporting
period, then a statement to this effect is required.

9.   BOOKS AND RECORDS

     9.1  Licensee shall keep accurate books and records showing all Licensed
Product manufactured, used and/or sold under the terms of this Agreement. Books
and records must be preserved for at least five (5) years from the date of the
royalty payment to which they pertain.

     9.2  Books and records pertaining to this Agreement must be open to
inspection by representatives or agents of The Regents at reasonable times, no
more than once in any twelve (12) month period and under reasonable conditions
of confidentiality. The Regents shall bear the fees and expenses of examination
but if it is discovered in any examination that Licensee has underpaid by more
than [*** Redacted] percent ([*** Redacted]%) the royalties due for any year,
then Licensee shall bear the fees and expenses of that examination.

10.  LIFE OF THE AGREEMENT

     10.1 Unless otherwise terminated by operation of law or by acts of the
parties in accordance with the terms of this Agreement, this Agreement will be
in force from the Effective Date until the date of expiration of the
last-to-expire patent licensed under this Agreement; or until the last patent
application licensed under this Agreement is abandoned and no patent in
Regents' Patent Rights ever issues.

     10.2 Any termination of this Agreement will not affect the rights and
obligations set forth in the following Articles:

               Article 9           Books and Records

               Article 13          Disposition of Licensed Product on Hand Upon
                                   Termination

               Article 14          Use of Names and Trademarks

               Article 19          Indemnification

               Article 23          Failure to Perform

               Article 28          Secrecy

*** Confidential treatment requested pursuant to a request for confidential
treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission.

                                       14
<PAGE>
11.  TERMINATION BY THE REGENTS

     If Licensee materially breaches this Agreement, then The Regents may give
written notice of default ("Notice of Default") to Licensee. If Licensee fails
to cure the breach within [*** Redacted] ([*** Redacted]) [*** Redacted] of the
effective date of Notice of Default, then The Regents may terminate this
Agreement and its licenses by a second written notice ("Notice of Termination");
provided that if Licensee in good faith disputes The Regents' right to terminate
this Agreement during the foregoing [*** Redacted] ([*** Redacted]) [***
Redacted] period, then termination of this Agreement shall not become effective
unless and until (i) the parties have met and attempted to resolve their dispute
by good faith negotiations for at least a period of [*** Redacted] ([***
Redacted]) [*** Redacted] after the Notice of Termination (the "Resolution
Period"), and are unable to do so, and (ii) in the event Licensee files a legal
action prior to the end of the Resolution Period challenging such termination,
unless and until it has been finally determined by a court of competent
jurisdiction that The Regents has the right to terminate this Agreement due to a
material breach by License, and Licensee fails to perform its obligations within
[*** Redacted] ([*** Redacted]) [*** Redacted] after such determination. Such
termination will not relieve Licensee of its obligation to pay any fees owing at
the time of termination and will not impair any accrued right of The Regents.
These notices are subject to Article 20 (Notices).

12.  TERMINATION BY LICENSEE

     12.1  Licensee has the right at any time to terminate this Agreement in
whole or as to any portion of Regents' Patent Rights by giving notice in writing
to The Regents. Such notice of termination will be subject to Article 20
(Notices) and termination of this Agreement will be effective [*** Redacted]
([*** Redacted]) [*** Redacted] from the effective date of such notice.

     12.2  Any termination under the above Paragraph 13.1 does not relieve
Licensee of any obligation or liability accrued under this Agreement prior to
termination or rescind any payment made to The Regents or anything done by
Licensee prior to the time termination becomes effective. Termination does not
affect in any manner any rights of The Regents arising under this Agreement
prior to termination.

13.  DISPOSITION OF LICENSED PRODUCT ON HAND UPON TERMINATION

     Upon termination of this Agreement, Licensee is entitled to dispose of all
previously made or partially made Licensed Product, but no more, within a
period of [*** Redacted] ([*** Redacted]) [*** Redacted].

*** Confidential treatment requested pursuant to a request for confidential
treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission.

                                       15
<PAGE>
provided that the sale of Licensed Product is subject to the terms of this
Agreement, including, but not limited to, the rendering of reports and payment
of royalties required under this Agreement.

14.  USE OF NAMES AND TRADEMARKS

     14.1  Nothing contained in this Agreement confers any right to use in
advertising, publicity or other promotional activities any name, trade name,
trademark or other designation of either party hereto (including contraction,
abbreviation or simulation of any of the foregoing). Unless required by law, the
use by Licensee of the name "The Regents of the University of California" or the
name of any campus of the University of California is prohibited.

     14.2  The Regents is free to release to the inventors and senior
administrators employed by The Regents the terms and conditions of this
Agreement. If such release is made, then The Regents shall give notice of the
confidential nature and shall request that the recipient does not disclose such
terms and conditions to others. If a third party inquires whether a license to
Regents' Patent Rights is available, then The Regents may disclose the existence
of this Agreement and the extent of the grant in Article 2 (Life of Patent
Exclusive Grant) to such third party, but will not disclose the name of Licensee
or any other terms or conditions of this Agreement, except where The Regents is
required to release information under either the California Public Records Act,
a governmental audit requirement or other applicable law. Licensee may disclose
this Agreement to its advisors, actual or potential investors or business or
acquisition partners, and others on a need-to-know basis under reasonable
conditions of confidentiality.

15.  LIMITED WARRANTY

     15.1  The Regents warrants to Licensee that it has the lawful right to
grant this license.

     15.2  This license and the associated Invention are provided WITHOUT
WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR ANY OTHER
WARRANTY, EXPRESS OR IMPLIED. THE REGENTS MAKES NO REPRESENTATION OR WARRANTY
THAT LICENSED PRODUCT OR LICENSED METHOD WILL NOT INFRINGE ANY PATENT OR OTHER
PROPRIETARY RIGHT.

     15.3  IN NO EVENT SHALL THE REGENTS OR LICENSEE BE LIABLE FOR ANY
INCIDENTAL, SPECIAL, INDIRECT, EXEMPLARY, PUNITIVE OR CONSEQUENTIAL DAMAGES
(INCLUDING LOST PROFITS OR REVENUES) RESULTING FROM EXERCISE OF THIS LICENSE OR
THE USE OF THE INVENTION OR LICENSED PRODUCT OR

                                       16
<PAGE>
OTHERWISE FROM THIS AGREEMENT, WHETHER IN CONTRACT, WARRANTY, TORT, STRICT
LIABILITY OR OTHERWISE, EXCEPT TO THE EXTENT LICENSEE MAY BE REQUIRED TO
INDEMNIFY THE REGENTS FROM SUCH DAMAGES CLAIMED BY THIRD PARTIES UNDER ARTICLE
19, AND EXCEPT FOR AN INTENTIONAL BREACH OF ARTICLE 28.

     15.4  This Agreement does not:

           15.4.1 express or imply a warranty or representation as to the
                  validity or scope of any of Regents' Patent Rights;

           15.4.2 express or imply a warranty or representation that anything
                  made, used, sold, offered for sale or imported or otherwise
                  disposed of under any license granted in this Agreement is or
                  will be free from infringement of patents of third parties;

           15.4.3 obligate The Regents to bring or prosecute actions or suits
                  against third parties for patent infringement except as
                  provided in Article 18 (Patent Infringement);

           15.4.4 confer by implication, estoppel or otherwise any license or
                  rights under any patents of The Regents other than Regents'
                  Patent Rights as defined in this Agreement, regardless of
                  whether those patents are dominant or subordinate to Regents'
                  Patent Rights; or

           15.4.5 obligate The Regents to furnish any know-how not provided in
                  Regents' Patent Rights.

16.  PATENT PROSECUTION AND MAINTENANCE

     16.1  As long as Licensee has paid patent costs as provided for in this
Article 17 (Patent Prosecution and Maintenance), The Regents shall diligently
endeavor to prosecute and maintain the U.S. and foreign patents comprising
Regents' Patent Rights using counsel of its choice, and The Regents shall
provide Licensee in advance (sufficient to provide Licensee with a reasonable
opportunity to review and comment prior to submission thereof) with drafts and
copies of all relevant documentation so that Licensee may be informed of the
continuing prosecution, and Licensee agrees to keep the documentation
confidential pursuant to Article 28 (Secrecy). The Regents' counsel will take
instructions only from The Regents, and all patents and patent applications
under this Agreement will be assigned solely to The Regents.

                                       17
<PAGE>
     16.2 The Regents shall use reasonable efforts to include, or amend to
include, in any patent application claims reasonably requested by Licensee to
protect the products contemplated to be sold under this Agreement, and to
otherwise reasonably consider any comments with respect to the prosecution of
Regents' Patent Rights provided by Licensee.

     16.3 Licensee shall bear the out-of-pocket costs of preparing, filing,
prosecuting and maintaining all U.S. and foreign patent applications within
Regents' Patent Rights contemplated by this Agreement. Costs billed by The
Regents' counsel will be rebilled to Licensee and are due within thirty (30)
days of rebilling by The Regents. These costs include patent prosecution costs
for the Invention incurred by The Regents prior to the execution of this
Agreement and any patent prosecution costs that may be incurred for
patentability opinions, re-examination, re-issue, interferences or inventorship
determinations. Prior prosecution costs will be due upon execution of this
Agreement and billing by The Regents. The Regents acknowledge that certain
prosecution costs have already been paid by Licensee pursuant to the parties'
Letter of Intent, dated September 13, 2001.

     16.4 Licensee may request The Regents to obtain patent protection on the
Invention in foreign countries if available and if it so desires. Licensee shall
notify The Regents of its decision to obtain or maintain foreign patents not
less than [*** Redacted] ([*** Redacted]) [*** Redacted] prior to the deadline
for any payment, filing or action to be taken in connection therewith. This
notice concerning foreign filing must be in writing, must identify the countries
desired and must reaffirm Licensee's obligation to underwrite the costs thereof.
The absence of such a notice from Licensee to The Regents will be considered an
election not to obtain or maintain foreign rights.

     16.5 Licensee's obligation to underwrite and to pay patent prosecution
costs will continue for so long as this Agreement remains in effect, but
Licensee may terminate its obligations with respect to any given patent
application or patent upon [*** Redacted] ([*** Redacted]) [*** Redacted]
written notice to The Regents. The Regents will use its best efforts to curtail
patent costs when a notice of termination is received from Licensee. The Regents
may prosecute and maintain such application(s) or patent(s) at its sole
discretion and expense, but Licensee will have no further right or licenses
thereunder. Nonpayment of patent costs may be deemed by The Regents as an
election by Licensee not to maintain application(s) or patent(s); provided that
The Regents' notify Licensee of such nonpayment and its intent to deem Licensee
to have made such election, and Licensee does not make the required payment
within [*** Redacted] ([*** Redacted]) [*** Redacted] thereafter.

*** Confidential treatment requested pursuant to a request for confidential
treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission.

                                       18
<PAGE>
     16.6  The Regents may file, prosecute or maintain patent applications at
its own expense in any country in which Licensee has not elected to file,
prosecute or maintain patent applications in accordance with this Article 16
(Patent Prosecution and Maintenance) and those applications and resultant
patents will not be subject to this Agreement.

17.  PATENT MARKING

     Licensee shall mark all Licensed Product made, used or sold under the terms
of this Agreement, or their containers, in accordance with the applicable patent
marking laws.

18.  PATENT INFRINGEMENT

     18.1  If Licensee learns of the substantial infringement of any patent
licensed under this Agreement, then Licensee shall call The Regents' attention
thereto in writing and provide The Regents with reasonable evidence of
infringement of which Licensee is aware. Neither party will notify a third party
of the infringement of any of Regents' Patent Rights without first obtaining
consent of the other party, which consent will not be unreasonably denied. Both
parties shall use their best efforts in cooperation with each other to terminate
infringement without litigation. It is understood that nothing in this Article
18 shall obligate the Licensee to sublicense any third party.

     18.2  Licensee may request that The Regents take legal action against the
infringement of Regents' Patent Rights. Such request must be in writing and must
include reasonable evidence of infringement and damages to Licensee. If the
infringing activity has not abated within [*** Redacted] ([*** Redacted]) [***
Redacted] following the effective date of request, then The Regents has the
right to:

           18.2.1 commence suit on its own account; or

           18.2.2 refuse to participate in the suit, and

     The Regents shall give notice of its election in writing to Licensee by the
end of the [*** Redacted] ([*** Redacted]) [*** Redacted] after receiving notice
of written request from Licensee. Licensee may thereafter bring suit for patent
infringement, at its own expense, if and only if The Regents elects not to
commence suit, or does not respond to Licensee within such [*** Redacted]
period, and if the infringement occurred during the period and in a jurisdiction
and field of use where Licensee had exclusive rights under this Agreement apart
from the license to the government hereunder. If, however, Licensee elects to
bring suit in accordance with this Paragraph 19.2, then The Regents may
thereafter join that suit at its own expense. Licensee agrees not to bring suit
for patent infringement without following the procedures of this Paragraph, and
both parties agree to be bound by an order

*** Confidential treatment requested pursuant to a request for confidential
treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission.

                                       19
<PAGE>
of a court for patent infringement, patent infringement issues and patent
infringement defenses raised through the pendency of such a suit under this
Paragraph 19.2.

     18.3  Legal action, as is decided on, will be at the expense of the party
bringing suit and all damages recovered thereby will belong to the party
bringing suit, but legal action brought jointly by The Regents and Licensee and
fully participated in by both will be at the joint expense of the parties and
all recoveries will be shared jointly by them in proportion to the share of
expense paid by each party. If The Regents brings suit solely in their own name
without participation by Licensee, then Licensee shall have the option, up to
[*** Redacted] ([*** Redacted]) [*** Redacted] after the filing of the suit, to
pay [*** Redacted] ([*** Redacted]) of The Regents' attorneys fees and all
costs, including internal costs, directly related to the suit and share equally
with The Regents' in The Regents' recoveries attributable to a period and
jurisdiction in which Licensee's rights are exclusive. The Regents shall keep
Licensee informed of its internal costs directly related to the suit and its
accounting thereof from time to time as requested by Licensee.

      18.4  Each party shall cooperate with the other (including participate,
but only to the extent necessary) in litigation proceedings instituted hereunder
at the expense of the party bringing suit. Litigation will be controlled by the
party bringing the suit, except that The Regents may be represented by counsel
of its choice in any suit brought by Licensee.

19.   INDEMNIFICATION

      19.1  Licensee shall indemnify, hold harmless and defend The Regents, its
officers, employees and agents, the sponsors of the research that led to the
Invention, in their role as sponsors, and the inventors of the patents and
patent applications in Regents' Patent Rights and their employers, in their role
as investors and employers thereof, against any and all third party claims,
suits, losses, liabilities, damages, costs, fees and expenses ("Claims")
resulting from or arising out of exercise of this license or any sublicense,
except to the extent resulting solely from willful misconduct or a breach of
this Agreement by The Regents; provided that Licensee is promptly notified in
writing of such Claims, has sole control of the defense and settlement thereof,
and obtains full cooperation and information from the indemnitee. Licensee shall
have no obligation for fees, costs or expenses incurred without Licensee's prior
written consent, not unreasonably withheld. It is understood that only The
Regents may claim indemnity under Article 19 (on its own behalf or on behalf of
the other above listed indemnitees), and other above listed indemnitees may not
directly

*** Confidential treatment requested pursuant to a request for confidential
treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission.

                                       20
<PAGE>
claim indemnity hereunder. This indemnification includes, but is not limited
to, any product liability.

     19.2 Licensee, at its sole cost and expense, shall insure its activities
in connection with the work under this Agreement and obtain, keep in force and
maintain insurance as follows or an equivalent program of self-insurance.

     19.3 Comprehensive or commercial form general liability insurance
(contractual liability included ) with limits as follows:

                         -    Each Occurrence $[*** Redacted]

                         -    Products/Completed Operations Aggregate $[***
                              Redacted]

                         -    Personal and Advertising Injury $[*** Redacted]

                         -    General Aggregate (commercial form only)
                              $[*** Redacted]

     The coverage and limits referred to under the above do not in any way limit
the liability of Licensee. Licensee shall furnish The Regents with certificates
of insurance showing compliance with all requirements. Certificates must:

                         -    Provide for thirty (30) days' advance written
                              notice to The Regents of any modification.

                         -    Indicate that The Regents has been endorsed as an
                              additional Insured under the coverage referred to
                              under the above.

                         -    Include a provision that the coverage will be
                              primary and will not participate with nor will be
                              excess over any valid and collectable insurance or
                              program of self-insurance carried or maintained by
                              The Regents.

     19.4 The Regents shall notify Licensee in writing of any claim or suit
brought against The Regents in respect of which The Regents intends to invoke
the provisions of this Article 19 (Indemnification). Licensee shall keep The
Regents informed on a current basis of its defense of any claims under this
Article 20 (Indemnification).

20.  NOTICES

     20.1 Any notice or payment required to be given to either party shall be
deemed to have been properly given and to be effective as of the date specified
below if delivered to the respective address given below or to another address
as designated by written notice given to the other party:

     20.1.1    on the date of delivery if delivered in person;

*** Confidential treatment requested pursuant to a request for confidential
treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission.

                                       21
<PAGE>
     20.1.2 on the date of mailing if mailed by first-class certified mail,
postage paid; or

     20.1.3 on the date of mailing if mailed by any global express carrier
service that requires recipient to sign the documents demonstrating the
delivery of such notice or payment.

     In the case of Licensee:        Nanosys, Inc.
                                     2625 Hanover St.
                                     Palo Alto, CA 94304
                                     Attention: President

     with a copy to:                 Wilson, Sonsini, Goodrich & Rosati
                                     650 Page Mill Road
                                     Palo Alto, California 94304
                                     Attention: Michael J. O'Donnell, Esq.

     In the case of The Regents:     The Regents of the University of California
                                     Office of Technology Transfer
                                     1111 Franklin Street, 5th Floor
                                     Oakland, CA 94607-5200
                                     Attention:   Executive Director
                                                  Research Administration and
                                                  Technology Transfer
                                     RE:   UC Case No. [*** Redacted]

21.  ASSIGNABILITY

     This Agreement may be assigned by The Regents, but is personal to Licensee
and assignable by Licensee only with the written consent of The Regents, which
consent will not be unreasonably withheld; provided, however, that Licensee
shall be entitled to assign this Agreement and all rights hereunder, upon
notice but without the consent of The Regents, in connection with a merger,
consolidation, sale or transfer of all or substantially all of the Licensee's
assets or business pertaining hereto, or its equity.

*** Confidential treatment requested pursuant to a request for confidential
treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission.

                                       22
<PAGE>
22.  NO WAIVER

     No waiver by either party of any default of this Agreement may be deemed a
waiver of any subsequent or similar default. A suspension of duty under this
Agreement due to force majeure shall not be for a period longer than one (1)
year.

23.  FAILURE TO PERFORM

     If either party finds it necessary to undertake legal action against the
other on account of failure of performance due under this Agreement, then the
prevailing party is entitled to reasonable attorney's fees in addition to costs
and necessary disbursements.

24.  GOVERNING LAWS

     THIS AGREEMENT WILL BE INTERPRETED AND CONSTRUED IN ACCORDANCE WITH THE
LAWS OF THE STATE OF CALIFORNIA WITHOUT REGARD TO CONFLICT OF LAWS OR TO WHICH
PARTY DRAFTED PARTICULAR PROVISIONS OF THIS AGREEMENT, but the scope and
validity of any patent or patent application will be governed by the
applicable laws of the country of the patent or patent application. Disputes
between the parties regarding this Agreement will utilize only trial courts
within California for disputes that go to court.

25.  PREFERENCE FOR U.S. INDUSTRY

     Because this Agreement grants the exclusive right to use or sell the
Invention in the U.S., Licensee agrees that any products sold in the U.S.
embodying this Invention or produced through the use thereof will be
manufactured substantially in the U.S., to the extent required by law.

26.  GOVERNMENT APPROVAL OR REGISTRATION

     Licensee shall notify The Regents if it becomes aware that this Agreement
is subject to any U.S. or foreign government reporting or approval requirement.
Licensee shall make all necessary filings and pay all costs including fees,
penalties and all other out-of-pocket costs associated with such reporting or
approval process.

27.  EXPORT CONTROL LAWS

     Licensee shall observe all applicable U.S. and foreign laws with respect
to the transfer of Licensed Product and related technical data to foreign
countries, including, without limitation, the International Traffic in Arms
Regulations (ITAR) and the Export Administration Regulations.

                                       23
<PAGE>
28.  SECRECY

     28.1  With regard to confidential information, which can be oral or written
or both, received hereunder by either party from the other party, which are
marked "Confidential" if disclosed in written or other tangible form, or
designated as confidential at the time of first disclosure and confirmed in a
written notice provided within [*** Redacted] ([*** Redacted]) [*** Redacted]
thereafter, if disclosed orally (the "Confidential Information"), each party
agrees:

          28.1.1  not to use the Confidential Information of the other party
                  except for the sole purpose of performing or exercising rights
                  under the terms of this Agreement;

          28.1.2  to safeguard the Confidential Information of the other party
                  against disclosure to others with the same degree of care as
                  it exercises with its own data of a similar nature, but in no
                  event less than reasonable care;

          28.1.3  not to disclose the Confidential Information of the other
                  party to third parties (except to its employees, agents or
                  consultants who are bound by a like obligation of
                  confidentiality) without the express written permission of the
                  other party

28.2  Notwithstanding the foregoing, Confidential Information shall not include
any information that the receiving party can demonstrate:

          28.2.1  was previously known to it;

          28.2.2  is now or becomes in the future, public knowledge other than
                  through acts or omissions of the receiving party; or

          28.2.3  is lawfully obtained by the receiving party from sources
                  independent of the other party, and without restrictions on
                  its use;

          28.2.4  was independently developed by the receiving party, without
                  use of or reference to the Confidential Information of the
                  other party; or

          28.2.5  is required to be disclosed by law; provided that the
                  receiving party promptly notifies the disclosing party and
                  removes the actual trade secrets of the disclosing party upon
                  request.

28.3  The secrecy obligations of Licensee and The Regents with respect to the
Confidential Information will continue for a period ending [*** Redacted] ([***
Redacted]) [*** Redacted] from the termination date of this Agreement.

*** Confidential treatment requested pursuant to a request for confidential
treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission.

                                       24
<PAGE>
29.  MISCELLANEOUS

     29.1 The headings of the several sections are inserted for convenience of
reference only and are not intended to be a part of or to affect the meaning or
interpretation of this Agreement.

     29.2 This Agreement is not binding on the parties until it has been signed
below on behalf of each party. It is then effective as of the Effective Date.

     29.3 No amendment or modification of this Agreement is valid or binding on
the parties unless made in writing and signed on behalf of each party.

     29.4 This Agreement embodies the entire understanding of the parties and
supersedes all previous communications, representations or understandings,
either oral or written, between the parties relating to the subject matter
hereof. The Letter of Intent (UC Control No. [*** Redacted]) dated September 13,
2001 and its extension and the Secrecy Agreement (UC Control No. [*** Redacted])
effective February 8, 2002 are hereby terminated.

     29.5 In case any of the provisions contained in this Agreement is held to
be invalid, illegal or unenforceable in any respect, that invalidity, illegality
or unenforceability will not affect any other provisions of this Agreement and
this Agreement will be construed as if the invalid, illegal or unenforceable
provisions had never been contained in it.

     29.6 None of the provisions of this Agreement is intended to create any
form of joint venture between the parties, rights in third parties or rights
that are enforceable by any third party.

     IN WITNESS WHEREOF, both The Regents and Licensee have executed this
Agreement, in duplicate originals, by their respective and duly authorized
officers on the day and year written.

NANOSYS, INC.                           THE REGENTS OF THE UNIVERSITY OF
                                        CALIFORNIA

By: /s/ Lawrence A. Bock                By: /s/ [*** Redacted]
    ---------------------------------       -----------------------------------
              (Signature)                              (Signature)

Name: Lawrence A. Bock                  Name: [*** Redacted]
      -------------------------------
             (Please Print)

Title: PRESIDENT AND CEO                Title: [*** Redacted]
       ------------------------------

Date: 06-10-02                          Dated: June 17, 2002
      -------------------------------          --------------------------------

Approved as to legal form: /s/ Sandra S. Schultz        6/29/02
                           ------------------------  -------------
                           Sandra S. Schultz         Date
                           University Counsel
                           Office of General Counsel

                                       25

*** Confidential treatment requested pursuant to a request for confidential
treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission.<PAGE>
                                                                   EXHIBIT 10.17

               NANOSYS/CW GROUP/LAWRENCE A. BOCK STATUS AGREEMENT

      This Agreement is effective as of February 10, 2004, by and among Nanosys,
Inc., a Delaware corporation (the "Company"), Lawrence A. Bock ("LB"), CW Group,
Inc., CW Ventures III, L.P., CW Ventures III - A Co-Investment Fund, L.P., J.P.
Morgan/CW Ventures III (Nanosys), L.P., and CW Partners IV, L.L.C. (along with
the general partners of all of the foregoing and any other venture capital funds
managed by such general partners and their affiliates, collectively "CW Group"),
Barry Weinberg, Walter Channing and Charles Hartman.

1. Board Observation Rights. CW Group will be entitled to the following
contractual board observer rights, in addition to rights to nonpublic financial
information, inspection rights and any other rights specifically provided to CW
Group by the Company under the Second Amended and Restated Investors' Rights
Agreement, by and between the Company and the investors named therein, dated as
of April 10, 2003, as amended: The Company shall invite CW Group to select one
representative of CW Group reasonably acceptable to the Company (the
"Representative") to attend in a nonvoting observer capacity meetings of its
Board of Directors; provided, however, that the Company reserves the right to
exclude CW Group's Representative from access to any material or meeting or
portion thereof if (i) the Company believes upon advice of counsel that such
exclusion is reasonably necessary to preserve the attorney-client privilege
between the Company and its counsel; (ii) access to such information or
attendance at such meeting could create a conflict of interest between CW Group
or CW Group's Representative, on the one hand, and the Company, on the other
hand, or (iii) such portion of a meeting is an executive session limited solely
to members of the Board of Directors and legal counsel.

      CW Group agrees, and any Representative designated by CW Group will agree
in writing, to hold in confidence and trust and to act in a fiduciary manner
with respect to all information provided to CW Group or CW Group's
Representative in connection with CW Group's rights under this Section 1, except
to the extent in the public domain at the time of such provision, subsequently
released into the public domain (through no fault of CW Group or CW Group's
Representative), or otherwise required by law and any other regulatory process
to which CW Group is subject; provided that CW Group may disclose information of
a non-technical nature, including financial information, to CW Group's partners,
members and affiliates. Notwithstanding the foregoing, except for summary
financial information about the Company which CW Group delivers to CW Group's
partners, members and affiliates pursuant to CW Group's regular reporting
practices, CW Group will only disclose information provided to CW Group in
connection with CW Group's rights under this Agreement to those of CW Group's
partners, members and affiliates who have agreed in writing to keep such
information confidential or who are provided with a copy of Section 1 of this
Agreement and agree to be bound by the terms of this Section 1 to the same
extent as if they were parties hereto.

      The rights described in this Section 1 shall terminate and be of no
further force or effect upon the earlier of: (i) the closing of a firm
commitment underwritten public offering of the Company's securities pursuant to
an effective registration statement filed by the Company under the Securities
Act of 1933, as amended; or (ii) the first date that CW Group and CW Group's
affiliates no longer hold, in the aggregate, at least 250,000 shares of the
Company's Series A

<PAGE>

Preferred Stock (or shares of the Company's Common Stock issued upon conversion
thereof). The confidentiality provision of this Section 1 will survive any such
termination. This Section 1 amends and restates in its entirety the Amended and
Restated Observation Rights Letter, by and between the Company and CW Group,
dated as of April 10, 2003.

2. Board Nominee of CW Group. CW Group hereby terminates its rights to designate
a member of the Board of Directors of the Company pursuant to the Second Amended
and Restated Voting Agreement, dated as of April 10, 2003, as amended.

3. Company Spin-Out Transaction. If (i) the Company proposes to consummate a
spin-out transaction of technology of the Company into a medical device company
(a "New Entity"), (ii) the initial equity financing of such New Entity by
venture capital entities (the "Initial Funding") occurs within one year from the
date hereof, and (iii) the New Entity offers to venture capital entities that
invested in the Company's Series A Preferred Stock Financing a right to invest
in the Initial Funding, then the Company agrees to discuss in good faith with
the New Entity a potential investment by CW Group in such New Entity and to use
reasonable efforts to enable CW Group to participate in the Initial Funding,
provided that (i) the ability of CW Group to invest in the New Entity, and any
decision by the New Entity whether to offer CW Group a right to invest in the
Initial Funding, will be determined in the sole discretion of the Board of
Directors of the New Entity and (ii) the obligations of the Company under this
Section 3 shall only apply to the first New Entity spun-out from the Company.

4. Employment of LB by Nanosys. The Company intends to hire LB as a full-time
employee effective April 1, 2004. After April 1, 2004, CW Group shall have no
obligation to continue to pay LB's salary.

5. Stock/Option Grants.

      (a) The Company shall grant to LB a stock purchase right to purchase
      950,000 shares of Common Stock of the Company vesting as set forth below
      (the "LB Grant"). Such stock grant shall have a purchase price per share
      equal to the fair market value of the Company's Common Stock on the date
      of grant, as determined in the sole discretion of the Company's Board of
      Directors. Such stock grant shall vest as follows: 1/60th of the number of
      shares shall vest one month from February 10, 2004 and 1/60th of the
      number of shares vest each full month thereafter until all of such shares
      vest, subject to LB's continued service relationship with the Company on
      each such date. Any shares of Common Stock purchased pursuant to LB Grant
      shall be subject to the Company's right of repurchase (at a price per
      share equal to the original purchase price) of the unvested portion of
      such shares.

      (b) In connection with Barry Weinberg and Walter Channing providing
      consulting services to the Company, the Company hereby agrees to grant to
      each of Barry Weinberg and Walter Channing an option or stock purchase
      right to purchase 50,000 shares of the Common Stock of the Company (the
      "Weinberg/Channing Grants") (for a combined aggregate of 100,000 shares
      under the Weinberg/Channing Grants). Such option or stock

                                       2
<PAGE>

      grants shall have an exercise or purchase price per share equal to the
      fair market value of the Company's Common Stock on the date of grant, as
      determined in the sole discretion of the Company's Board of Directors.
      Such options or stock grants shall vest as follows: 1/60th of the number
      of shares shall vest one month from February 10, 2004 and 1/60th of the
      number of shares shall vest each full month thereafter until all of such
      shares vest, subject to Mr. Weinberg's and Mr. Channing's, as applicable,
      continued service relationship with the Company on each such date. If
      options are granted, such options shall be immediately exercisable in full
      on the date of grant. Any shares of Common Stock purchased pursuant to the
      Weinberg/Channing Grants shall be subject to the Company's right of
      repurchase (at a price per share equal to the original exercise or
      purchase price) of the unvested portion of such shares. Mr. Weinberg and
      Mr. Channing hereby agree to be consultants to the Company and to remain
      available to provide consulting services to the Company upon request and
      without charge, provided that the consulting relationships of Mr. Weinberg
      and Mr. Channing shall not be terminable by the Company until the earlier
      of (i) the time that Larry Bock is no longer a service provider to the
      Company or (ii) the Weinberg/Channing Grants vest in full.

      (c) In connection with Charles Hartman providing consulting services to
      the Company with regard to the formation of the New Entity, the Company
      hereby agrees to issue to Charles Hartman an option or stock purchase
      right (the "CH Grant") to purchase 50,000 shares of Common Stock of the
      Company, with an exercise or purchase price per share equal to the fair
      market value of the Company's Common Stock on the date of grant, as
      determined in the sole discretion of the Company's Board of Directors.
      Such option or stock grant shall vest as follows: 1/60th of the number of
      shares shall vest one month from February 10, 2004 and 1/60th of the
      number of shares shall vest each full month thereafter until all of such
      shares vest, subject to Mr. Hartman's continued service relationship with
      the Company on each such date. Notwithstanding the foregoing, upon the
      closing of an Initial Funding of a New Entity, all of the shares subject
      to the CH Grant shall vest in full. If options are granted, such options
      shall be immediately exercisable in full on the date of grant. Any shares
      of Common Stock purchased pursuant to the CH Grant shall be subject to the
      Company's right of repurchase (at a price per share equal to the original
      exercise or purchase price) of the unvested portion of such shares. Mr.
      Hartman hereby agrees to be a consultant to the Company and to remain
      available to provide consulting services to the Company upon request and
      without charge.

6. No Other Rights to Compensation or to Acquire Company Securities. CW Group
hereby agrees and acknowledges that except as set forth in this Agreement CW
Group does not and will not have (i) any right to receive any compensation of
any kind, including, without limitation, equity, cash and other compensation,
from LB or the Company, whether as a result of the employment of LB by the
Company, the receipt of cash salary, bonus, or other compensation from the
Company or otherwise and (ii), other than the Weinberg/Channing Grants, the CH
Grant and any rights of first offer or co-sale that CW Group may have pursuant
to the Series C Preferred Stock financing transaction documents (as may be
amended from time to time), any right to acquire or receive, either from LB or
the Company, any securities of the Company,

                                       3
<PAGE>

including, but not limited to, the LB Grant or any other stock or options which
the Company may in the future issue to LB.

7. Vesting of LB in CW Group. CW Group (including, without limitation, CW
Partners IV, L.L.C.) intends that LB shall be fully vested in his interests in
CW Group (including, without limitation, CW Partners IV, L.L.C.). Accordingly,
the members of the CW Group, including, without limitation, CW Partners IV,
L.L.C., on behalf of themselves and their respective officers, directors,
employees, members, partners and affiliates (collectively, the "CW Parties"),
acknowledge and agree that each interest in any of the CW Parties held directly
or indirectly by Bock, his affiliates or his estate planning vehicles
(collectively, the "Bock Parties") as of the date of this Agreement is fully
vested and not subject, in whole or in part, to forfeiture, diminution, or
repurchase or to any lien, pledge or other encumbrance, pursuant to any
agreement or other arrangement to which any of the CW Parties is a party.

8. Reimbursement of COBRA Payments. After LB both (i) commences employment with
the Company to become a full-time employee of the Company and (ii) resigns from
CW Group, should LB elect COBRA under CW Group's health insurance plans the
Company shall reimburse LB for any COBRA payments LB may make to maintain LB's
health insurance coverage under CW Group health insurance plans.

9. Miscellaneous. This Agreement shall benefit and bind the parties and their
respective successors, heirs, legal representatives and permitted assigns. This
Agreement shall be governed by the laws of California without regard to
California conflicts of law rules. This Agreement constitutes the entire
agreement between the parties with respect to the subject matter hereof and
supersedes all prior written and oral agreements between the parties regarding
the subject matter hereof, provided that the parties hereto agree to execute all
further documentation necessary to carry out and fully implement the provisions
set forth herein, including stock option or stock purchase agreements from the
Company to LB, Charles Hartman, Barry Weinberg and Walter Channing, and release
of repurchase rights by CW Group, as reasonably determined necessary by legal
counsel to the parties, including, but not limited to, a Separation Agreement
between LB and CW Group. No provision of this Agreement may be waived except by
a writing executed by the party against whom the waiver is to be effective. A
party's failure to enforce any provision of this Agreement shall neither be
construed as a waiver of the provision nor prevent the party from enforcing any
other provision of this Agreement. No provision of this Agreement may be amended
or otherwise modified except by a writing signed by the parties to this
Agreement.

                                       4
<PAGE>

      This Agreement may be executed in two or more counterparts, each of which
shall be deemed an original and all of which together shall be deemed one
document.

                                       NANOSYS, INC.

                                           By:   /s/ Calvin Chow
                                              ----------------------------------
                                           Name: Calvin Chow
                                                --------------------------------
                                           Title:  CEO
                                                 -------------------------------

                                       LB:

                                                 /s/ Lawrence Bock
                                       -----------------------------------------
                                           Lawrence Bock

<PAGE>

                                       ACKNOWLEDGED, AGREED AND ACCEPTED:

                                       CW GROUP:

                                           CW GROUP, INC.

                                               By:   /s/ Charles Hartman
                                                  ------------------------------
                                               Name: Charles Hartman
                                                    ----------------------------
                                               Title:   Vice President
                                                     ---------------------------

                                           CW VENTURES III, L.P.

                                               By: /s/ Charles Hartman
                                                   -----------------------------
                                                   CW Partners IV, L.L.C.
                                                   General Partner

                                           CW VENTURES III - A CO-INVESTMENT
                                               FUND, L.P.

                                               By: /s/ Charles Hartman
                                                   -----------------------------
                                                   CW Partners IV, L.L.C.
                                                   General Partner

                                           J.P. MORGAN/CW VENTURES III
                                               (NANOSYS), L.P.

                                               By: /s/ Charles Hartman
                                                   -----------------------------
                                                   CW Partners IV, L.L.C.
                                                   General Partner

                                           CW PARTNERS IV, L.L.C.

                                               By: /s/ Charles Hartman
                                                  ------------------------------
                                               Name: Charles Hartman
                                                    ----------------------------
                                               Title: Managing Member, Partner
                                                     ---------------------------

<PAGE>

                                           ACKNOWLEDGED, AGREED AND ACCEPTED:

                                           BARRY WEINBERG:

                                               /s/ Barry Weinberg
                                               ---------------------------------
                                               Barry Weinberg

                                           WALTER CHANNING:

                                               /s/ Walter Channing
                                               ---------------------------------
                                               Walter Channing

                                           CHARLES HARTMAN:

                                               /s/ Charles Hartman
                                               ---------------------------------
                                               Charles Hartman

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00067-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00067-of-00352.parquet"}]]